Patents Assigned to Global Alliance for TB Drug Development
-
Patent number: 11964949Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.Type: GrantFiled: January 13, 2020Date of Patent: April 23, 2024Assignee: The Global Alliance for TB Drug Development, Inc.Inventors: Christopher B. Cooper, Haihong Huang, Dongfeng Zhang, Nader Fotouhi, Takushi Kaneko
-
Patent number: 11261200Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of tuberculosis.Type: GrantFiled: October 5, 2017Date of Patent: March 1, 2022Assignee: The Global Alliance for TB Drug Development, Inc.Inventors: Takushi Kaneko, Nader Fotouhi
-
Patent number: 10981891Abstract: The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.Type: GrantFiled: October 14, 2019Date of Patent: April 20, 2021Assignees: The Global Alliance for TB Drug Development, Inc., Janssen Pharmaceutica NVInventors: Anna Marie Upton, Christopher Blair Cooper, Koenraad Jozef Lodewijk Marcel Andries, Jerome Emile Georges Guillemont, Walter Marcel Mathilde Van den Broeck, Brian Desmond Palmer, Zhenkun Ma
-
Patent number: 10550092Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.Type: GrantFiled: July 15, 2016Date of Patent: February 4, 2020Assignee: The Global Alliance for TB Drug Development, Inc.Inventors: Christopher B. Cooper, Haihong Huang, Dongfeng Zhang, Nader Fotouhi, Takushi Kaneko
-
Patent number: 10508097Abstract: The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.Type: GrantFiled: March 7, 2017Date of Patent: December 17, 2019Assignees: The Global Alliance for TB Drug Development, Inc., Janssen Pharmaceutica NVInventors: Anna Marie Upton, Christopher Blair Cooper, Koenraad Jozef Lodewijk Marcel Andries, Jerome Emile Georges Guillemont, Walter Marcel Mathilde Van den Broeck, Brian Desmond Palmer, Zhenkun Ma
-
Patent number: 9198913Abstract: The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.Type: GrantFiled: July 30, 2010Date of Patent: December 1, 2015Assignee: Global Alliance for TB Drug DevelopmentInventors: William Alexander Denny, Andrew Mark Thompson, Adrian Blaser, Zhenkun Ma, Brian Desmond Palmer, Hamish Scott Sutherland, Iveta Kmentova
-
Patent number: 9163020Abstract: The invention provides compounds of formula (I) and methods of treating a Mycobacterium infection or tuberculosis, or inhibiting DprE1 with the same.Type: GrantFiled: July 10, 2014Date of Patent: October 20, 2015Assignees: Global Alliance for TB Drug Development, Foundation for Neglected Disease ResearchInventors: Pravin S. Shirude, Maruti N. Naik, Vikas Narayan Shinde, Shahul Hameed Peer Mohamed, Monalisa Chatterji, Radha K. Shindil
-
Publication number: 20140243327Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments. A general representation of the 2-(heteroaryl)amino-riminophenazines is shown below.Type: ApplicationFiled: May 1, 2014Publication date: August 28, 2014Applicant: Global Alliance for TB Drug DevelopmentInventors: Kai Liu, Christopher B. Cooper, Haihong Huang, Chun Li, Binna Liu, Yang Liu, Zhenkun Ma, Jingbin Wang, Dali Yin, Dongfeng Zhang, Gang Zhang, Hao Zhang
-
Patent number: 8716292Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments. A general representation of the 2-(heteroaryl)amino-riminophenazines is shown below.Type: GrantFiled: June 28, 2011Date of Patent: May 6, 2014Assignee: Global Alliance for TB Drug DevelopmentInventors: Kai Liu, Christopher B. Cooper, Haihong Huang, Chun Li, Binna Liu, Yang Liu, Zhenkun Ma, Jingbin Wang, Dali Yin, Dongfeng Zhang, Gang Zhang, Hao Zhang
-
Patent number: 8293734Abstract: The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.Type: GrantFiled: July 30, 2010Date of Patent: October 23, 2012Assignee: Global Alliance for TB Drug DevelopmentInventors: Andrew Mark Thompson, William Alexander Denny, Adrian Blaser, Zhenkun Ma
-
Publication number: 20120071472Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.Type: ApplicationFiled: June 28, 2011Publication date: March 22, 2012Applicants: Institute of Materia Medica, Global Alliance for TB Drug DevelopmentInventors: Kai Liu, Christopher B. Cooper, Haihong Huang, Chun Li, Binna Liu, Yang Liu, Zhenkun Ma, Jingbin Wang, Dali Yin, Dongfeng Zhang, Gang Zhang, Hao Zhang
-
Publication number: 20120028973Abstract: The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.Type: ApplicationFiled: July 30, 2010Publication date: February 2, 2012Applicant: Global Alliance for TB Drug DevelopmentInventors: William Alexander Denny, Andrew Mark Thompson, Adrian Blaser, Brian Desmond Palmer, Zhenkun Ma, Hamish Scott Sutherland, Iveta Kmentova
-
Publication number: 20110028466Abstract: The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.Type: ApplicationFiled: July 30, 2010Publication date: February 3, 2011Applicant: Global Alliance for TB Drug DevelopmentInventors: Andrew Mark Thompson, William Alexander Denny, Adrian Blaser, Zhenkun Ma
-
Patent number: 7666864Abstract: The current invention provides a series of bicyclic nitroimidazole-substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone, their pharmaceutical compositions, and the method of use of the compositions for prevention and treatment of bacterial infections. The bicyclic nitroimidazole-substituted phenyl oxazolidinones possess surprising antibacterial activity against wild-type and resistant strains of pathogens, and are therefore useful for the prevention, control and treatment of a number of human and veterinary bacterial infections caused by these pathogens, such as Mycobacterium tuberculosis.Type: GrantFiled: March 25, 2009Date of Patent: February 23, 2010Assignee: Global Alliance for TB Drug DevelopmentInventors: Charles Z. Ding, Genliang Lu, Keith Combrink, Dianjun D. Chen, Minsoo Song, Jiancheng Wang, Zhenkun Ma, Brian Desmond Palmer, Adrian Blaser, Andrew M. Thompson, Iveta Kmentova, Hamish Scott Sutherland, William Alexander Denny
-
Publication number: 20090281088Abstract: The current invention provides a series of bicyclic nitroimidazole-substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone, their pharmaceutical compositions, and the method of use of the compositions for prevention and treatment of bacterial infections. The bicyclic nitroimidazole-substituted phenyl oxazolidinones possess surprising antibacterial activity against wild-type and resistant strains of pathogens, and are therefore useful for the prevention, control and treatment of a number of human and veterinary bacterial infections caused by these pathogens, such as Mycobacterium tuberculosis.Type: ApplicationFiled: March 25, 2009Publication date: November 12, 2009Applicant: Global Alliance for TB Drug DevelopmentInventors: Charles Z. Ding, Genliang Lu, Keith Combrink, Dianjun D. Chen, Minsoo Song, Jiancheng Wang, Zhenkun Ma, Brian Desmond Palmer, Adrian Blaser, Andrew M. Thompson, Iveta Kmentova, Hamish Scott Sutherland, William Alexander Denny